New drug pair aims to shrink Hard-to-Treat breast tumors

NCT ID NCT05748834

Recruiting now Disease control Sponsor: SCRI Development Innovations, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. It tests two drugs together: tucatinib and Doxil. The goal is to see how well the combination shrinks tumors and to track any side effects. About 36 adults will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Alliance Cancer Specialists
RECRUITING

Bensalem, Pennsylvania, 19020, United States
Blue Ridge Cancer Care (Oncology & Hematology Assoc of SW Virginia, Inc)
RECRUITING

Salem, Virginia, 24153, United States
Maryland Oncology Hematology
RECRUITING

Columbia, Maryland, 21044, United States
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Tennessee Oncology
ACTIVE_NOT_RECRUITING

Nashville, Tennessee, 37203, United States
Texas Oncology- DFW
RECRUITING

Dallas, Texas, 75246, United States
Texas Oncology- San Antonio
RECRUITING

San Antonio, Texas, 78240, United States
Virginia Oncology Associates
RECRUITING

Norfolk, Virginia, 23502, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.